A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...
Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...
Indian pharmaceutical CDMOs are anticipated to encounter minimal disruptions from the proposed US tariffs of 10-25 per cent.
India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...
The Indian Pharmaceutical Alliance (IPA) has proposed reducing the import duty on pharma products from the US to zero.
Life Insurance Corporation of India (LIC) hopes to decide on acquiring stake in a health insurance company by the end of ...
Former Pharmexcil Director-General warns India against reducing import duties under US pressure, citing potential industry impact and loss of leverage.
Dehradun: An Indian pharmaceutical firm, whose products Singapore's Health Sciences Authority (HSA) allegedly issued images ...
The USFDA has established an office in India to oversee the number of Indian manufacturers qualified to supply generic ...
Indian pharma CDMOs remain resilient, continuing to thrive due to favorable global factors. The B&K Securities report ...
An Indian drug maker tells a BBC undercover team its addictive cocktail drug is “very harmful” but “this is business”.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results